Comparison of a Gastroprotective Agent and H2-Receptor Antagonist on Preventative and Therapeutic Effects against Gastroduodenal Mucosal Damage in Patients Taking Low-Dose Aspirin: a prospective, randomized, multicenter, controlled trial

INTERVENTION: The subjects were allocated to either the famotidine group (20 mg, once a day)hey were treated with each study medication for 12 weeks while taking LDA continuously the teprenone group (50 mg, three times a day.hey were treated with each study medication for 12 weeks while taking LDA continuously CONDITION: gastroduodenal ulcer PRIMARY OUTCOME: Endoscopy view (existence of ulcer development of symptoms) SECONDARY OUTCOME: A LANZA strange method score, subjective symptoms, a blood test (anemic existence), safety INCLUSION CRITERIA: criteria were that patients required continuous medication with LDA (80–300 mg/day) for 12 weeks or longer after participation in the study, regardless of past LDA treatment, that they were aged 20 years or older and that no peptic ulcer was detected on endoscopy at the start of treatment. Patients were included regardless of sex and whether or not they were outpatients. Exclusion criteria were as follows: